BridgeBio Pharma (BBIO) News Today $23.41 -0.38 (-1.60%) (As of 10/31/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $47.50 Average Target Price from BrokeragesOctober 26, 2024 | americanbankingnews.comBridgeBio shares preliminary data from CANaspire Phase 1/2 trial of BBP-812October 25, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for BridgeBio Pharma (NASDAQ:BBIO)HC Wainwright reissued a "buy" rating and set a $43.00 target price on shares of BridgeBio Pharma in a research note on Friday.October 25, 2024 | marketbeat.comBridgeBio Pharma Presents Positive Data From CANaspire Phase 1/2 Study In Canavan DiseaseOctober 24, 2024 | markets.businessinsider.comBridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024October 24, 2024 | globenewswire.comInvestors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three yearsOctober 24, 2024 | finance.yahoo.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fifteen brokerages that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and thirteen have assigned a buOctober 23, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) PT Lowered to $46.00 at Leerink PartnersLeerink Partners decreased their target price on shares of BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating for the company in a report on Thursday.October 17, 2024 | marketbeat.comEquities Analysts Offer Predictions for BridgeBio Pharma, Inc.'s Q3 2024 Earnings (NASDAQ:BBIO)BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Stock analysts at Leerink Partnrs decreased their Q3 2024 earnings per share (EPS) estimates for BridgeBio Pharma in a note issued to investors on Monday, October 14th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will posOctober 17, 2024 | marketbeat.comBridgeBio Pharma Receives ‘Buy’ Rating Amid Positive Regulatory Outlook for AcoramidisOctober 17, 2024 | markets.businessinsider.comBridgeBio Pharma (NASDAQ:BBIO) Now Covered by Analysts at ScotiabankScotiabank initiated coverage on shares of BridgeBio Pharma in a research report on Wednesday. They set a "sector outperform" rating on the stock.October 16, 2024 | marketbeat.comOptimistic Patent Litigation Outlook Strengthens Buy Rating for BridgeBio PharmaOctober 11, 2024 | markets.businessinsider.comBridgeBio Pharma (NASDAQ:BBIO) Shares Up 4.7% - Should You Buy?BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 4.7% - Here's What HappenedOctober 10, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Shares Down 4.6% - Here's What HappenedBridgeBio Pharma (NASDAQ:BBIO) Shares Down 4.6% - Time to Sell?October 9, 2024 | marketbeat.comMarshall Wace LLP Acquires Shares of 30,849 BridgeBio Pharma, Inc. (NASDAQ:BBIO)Marshall Wace LLP bought a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 30,849 shares of the company's stock, valued at approximately $781,000. Several other large investorsOctober 9, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Stock, Short Interest ReportOctober 7, 2024 | benzinga.com3 Top Stocks That Could Still Rocket Higher in 2024October 4, 2024 | fool.comAlgert Global LLC Has $1.42 Million Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Algert Global LLC trimmed its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 37.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,848 shares of the company's stock afterOctober 4, 2024 | marketbeat.comOppenheimer Initiates Coverage of BridgeBio Pharma (BBIO) with Perform RecommendationOctober 4, 2024 | msn.comBridgeBio granted Perform rating at Oppenheimer on market challengesOctober 3, 2024 | seekingalpha.comBridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific SessionsOctober 3, 2024 | globenewswire.comGhisallo Capital Management LLC Sells 33,750 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Ghisallo Capital Management LLC cut its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 50.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,750 shares of the company's stocOctober 2, 2024 | marketbeat.comBuy Recommendation for BridgeBio Pharma Amidst Promising Drug Trials and Upcoming FDA DecisionOctober 1, 2024 | markets.businessinsider.comHold Rating on BridgeBio Pharma Amid Acoramidis Regulatory Uncertainty and Market Prospects EvaluationSeptember 30, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on BridgeBio Pharma (BBIO)September 30, 2024 | markets.businessinsider.comBridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart DiseaseSeptember 30, 2024 | benzinga.comBridgeBio Pharma (NASDAQ:BBIO) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $43.00 target price on shares of BridgeBio Pharma in a report on Monday.September 30, 2024 | marketbeat.comBridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)September 30, 2024 | globenewswire.comPerceptive Advisors LLC Trims Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Perceptive Advisors LLC lowered its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 13.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,215,346 shares of the company's stock after selling 196,687 shares during the period. Perceptive AdvSeptember 30, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Stake Boosted by Frazier Life Sciences Management L.P.Frazier Life Sciences Management L.P. grew its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 6.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,632,604 shares oSeptember 29, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have received an average rating of "Moderate Buy" from the twelve analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eleven have issSeptember 28, 2024 | marketbeat.comBridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization EventsSeptember 27, 2024 | globenewswire.comLion Point Capital LP Takes Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Lion Point Capital LP acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 49,000 shares of the company's stock, valued at approximatelSeptember 27, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Federated Hermes Inc.Federated Hermes Inc. cut its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 94.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,500 shares of the company's stock after selling 75,028 shares during the quarteSeptember 26, 2024 | marketbeat.comHold Rating on BridgeBio Pharma Amid Regulatory Concerns and Competitive Challenges for AcoramidisSeptember 24, 2024 | markets.businessinsider.comEnsign Peak Advisors Inc Has $41.70 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Ensign Peak Advisors Inc lifted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 44.5% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,646,202 shares of the company's stock after buying an additional 506,845 sharesSeptember 22, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Increases Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Massachusetts Financial Services Co. MA boosted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 57.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 598,263 shares of the company's stock after purchasingSeptember 21, 2024 | marketbeat.comAmerican Century Companies Inc. Buys 182,623 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)American Century Companies Inc. lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 20.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,096,734 shares of the company's stock after buying an additional 182,623 shaSeptember 19, 2024 | marketbeat.com3 Best High-Growth Mid-Cap Stocks to Buy in September 2024September 18, 2024 | 247wallst.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Major Shareholder Sells $149,350,000.00 in StockSeptember 18, 2024 | insidertrades.comBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up to $26.19BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up to $26.19September 17, 2024 | marketbeat.comBridgeBio Says FDA Grants Breakthrough Therapy Designation To Oral Infigratinib For AchondroplasiaSeptember 17, 2024 | markets.businessinsider.comBridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDASeptember 17, 2024 | globenewswire.comBuy Rating Affirmed for BridgeBio Pharma Amidst Promising Gene Therapy Advancements and Regulatory MilestonesSeptember 16, 2024 | markets.businessinsider.comBridgeBio Pharma's (BBIO) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and issued a $70.00 target price on shares of BridgeBio Pharma in a report on Monday.September 16, 2024 | marketbeat.comBridgeBio Pharma's (BBIO) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $43.00 target price on shares of BridgeBio Pharma in a research report on Monday.September 16, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock Position Boosted by Daiwa Securities Group Inc.Daiwa Securities Group Inc. boosted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 5,393.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 35,709 shares of the company's stock after buyiSeptember 16, 2024 | marketbeat.comVictory Capital Management Inc. Has $9.69 Million Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Victory Capital Management Inc. raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 9.9% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 382,717 shares of the company's stock after purchasing an additional 34,360 shares durSeptember 15, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Shares Down 2.2% BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 2.2%September 13, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) to Post Q3 2024 Earnings of ($0.85) Per Share, Leerink Partnrs ForecastsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Equities researchers at Leerink Partnrs boosted their Q3 2024 earnings per share (EPS) estimates for BridgeBio Pharma in a report issued on Tuesday, September 10th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post eaSeptember 13, 2024 | marketbeat.com Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Don’t Miss Out! Get 2 Hot AI Stocks for Under $10/Share 🚀 (Ad)Artificial Intelligence (AI) stocks are booming, and now is your chance to get in on the action — without breaking the bank! We’ve just uncovered 2 must-buy AI stocks trading for under $10/share, and they’re showing serious potential for growth. Click here to get your FREE report delivered instantly! BBIO Media Mentions By Week BBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BBIO News Sentiment▼0.300.68▲Average Medical News Sentiment BBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BBIO Articles This Week▼56▲BBIO Articles Average Week Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Perrigo News Amicus Therapeutics News Arrowhead Pharmaceuticals News Schrödinger News Allakos News Genmab A/S News Summit Therapeutics News Viatris News Dr. Reddy's Laboratories News Vaxcyte News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BBIO) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.